Abatacept (Orencia®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014000448
English
Authors' recommendations:
Abatacept (Orencia®) is recommended as an option for use within NHS Wales in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs including at least one tumour necrosis factor inhibitor. This recommendation applies only in circumstances where the approved Wales Patients Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Child
- Arthritis, Juvenile
- Immunoconjugates
- Antirheumatic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.